Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731345 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL5731758 | 0.87 | APEX1 (0.50) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL5731759 | 0.87 | APEX1 (0.50) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL5731712 | 0.85 | TBXAS1 (0.48) | KDM4EALDH1A1PKMSMN1; SMN2HDAC4 | |
| SCHEMBL5731713 | 0.85 | TBXAS1 (0.48) | KDM4EALDH1A1PKMSMN1; SMN2HDAC4 | |
| SCHEMBL20546854 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL28357772 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL28357770 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL20546775 | 0.77 | TBXAS1 (0.52) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL20546918 | 0.77 | KDM4E (0.52) | KDM4EALDH1A1PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| EP-1008346-B1 | NF-kB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-6943196-B1 | NF-κB inhibitor comprising phenylmethyl benzoquinone as the active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-09-13 | — | — | US | disclosed |
| CN-1212861-C | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | DAIICHI SUNTORY PHARMACEATICAL (JP) | 2005-08-03 | — | — | CN | disclosed |
| CN-1181817-C | NF-KB inhibitors containing as active ingredient phenylmethyl benzoquinone | ��һ��������ҩ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| CN-1335777-A | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | SUNTORY LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| CN-1262618-A | NF-KB inhibitors containing as active ingredient phenylmethyl benzoquinone | SUNTORY LTD (JP) | 2000-08-09 | — | — | CN | disclosed |
| EP-1008346-A1 | NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | SUNTORY LIMITED (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | KDM4E 4836/4885ALDH1A1 1004/4885PKM 4882/4885 |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | NFKBIA, NFKB2, NFKB1 | KDM4E 651/4885ALDH1A1 1468/4885PKM 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.